A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex.
Mirabella F et al. PLoS One. 2014 Jun 12;9(6):e99493. doi: 10.1371/journal.pone.0099493. eCollection 2014.

MicroRNA expression patterns in medullary and extramedullary plasmacytoma.
Lin JJ et al. Blood Cancer J. 2014 Jun 27;4:e223. doi: 10.1038/bcj.2014.41.

An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.
Tucci M et al. Exp Hematol. 2014 Jun 24. pii: S0301-472X(14)00239-2. doi: 10.1016/j.exphem.2014.06.005. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/24971696.

The WWOX gene inhibits the growth of U266 multiple myeloma cells by triggering the intrinsic apoptotic pathway.
Zhang H et al. Int J Mol Med. 2014 Jun 27. doi: 10.3892/ijmm.2014.1824. [Epub ahead of print].

Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells.
Dotterweich J et al. Cell Commun Signal. 2014 Jun 25;12(1):36. [Epub ahead of print].

CSNK1α1 mediates malignant plasma cell survival.
Hu Y et al. Leukemia. 2014 Jun 25. doi: 10.1038/leu.2014.202. [Epub ahead of print].

p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.
Lu Y et al. Nat Commun. 2014 Jun 24;5:4229. doi: 10.1038/ncomms5229.

Liposomal Bortezomib Nanoparticles via Boronic Ester Prodrug Formulation for Improved Therapeutic Efficacy in Vivo.
Ashley JD et al. J Med Chem. 2014 Jun 26;57(12):5282-92. doi: 10.1021/jm500352v. Epub 2014 Jun 13.

A Gene Expression Based Predictor for High Risk Myeloma Treated with Intensive Therapy and Autologous Stem Cell Rescue.
Wu P et al. Leuk Lymphoma. 2014 Jun 10:1-20. [Epub ahead of print].

Carmustine induces platelet apoptosis.
Zhang J et al. Platelets. 2014 Jun 23:1-6. [Epub ahead of print].

Magnetically responsive smart nanoparticles for cancer treatment with a combination of magnetic hyperthermia and remote-control drug release.
Hayashi K et al. Theranostics. 2014 Jun 7;4(8):834-44. doi: 10.7150/thno.9199. eCollection 2014.

Polymorphisms in the heparanase (HSPE) gene in multiple myeloma – association with bone morbidity and survival.
Andersen NF et al. Eur J Haematol. 2014 Jun 21. doi: 10.1111/ejh.12401. [Epub ahead of print].

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.
Kuppusamy H et al. PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.

Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy.
Robinson CR et al. Brain Res. 2014 Jun 17. pii: S0006-8993(14)00816-6. doi: 10.1016/j.brainres.2014.06.013. [Epub ahead of print].

Cell pairing using microwell array electrodes based on dielectrophoresis.
Yoshimura Y et al. Anal Chem. 2014 Jun 20. [Epub ahead of print].

Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B et al. Cancer Immunol Immunother. 2014 Jun 20. [Epub ahead of print].

Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro.
Li Y et al. Leuk Res. 2014 Jun 4. pii: S0145-2126(14)00173-8. doi: 10.1016/j.leukres.2014.05.022. [Epub ahead of print].

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.
Westwood JA et al. Leuk Res. 2014 Jun 2. pii: S0145-2126(14)00151-9. doi: 10.1016/j.leukres.2014.05.010. [Epub ahead of print].

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N et al. Cancer Res. 2014 Jun 16. pii: canres.3652.2013. [Epub ahead of print].

Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress.
Zhongyu WU et al. Curr Med Chem. 2014 Jun 1. [Epub ahead of print].

Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma.
Zhu J et al. Curr Med Chem. 2014 Jun 1. [Epub ahead of print].

WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.
Aldaz CM et al. Biochim Biophys Acta. 2014 Jun 14. pii: S0304-419X(14)00050-X. doi: 10.1016/j.bbcan.2014.06.001. [Epub ahead of print].

Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Rupa-Matysek J et al. Thromb Res. 2014 Jun 2. pii: S0049-3848(14)00298-9. doi: 10.1016/j.thromres.2014.05.032. [Epub ahead of print].

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
Wang J et al. Blood. 2014 Jun 13. pii: blood-2014-03-562439. [Epub ahead of print].

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. A comparative study with nutlin3a.
Surget S et al. BMC Cancer. 2014 Jun 14;14(1):437. [Epub ahead of print].

The novel immunotoxin HM1.24-ETA’ induces apoptosis in multiple myeloma cells.
Staudinger M et al. Blood Cancer J. 2014 Jun 13;4:e219. doi: 10.1038/bcj.2014.38.

Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model.
Schwarzer R et al. Blood Cancer J. 2014 Jun 13;4:e217. doi: 10.1038/bcj.2014.37.

CARTs on the road for myeloma.
Maus M et al. Clin Cancer Res. 2014 Jun 11. pii: clincanres.0721.2014. [Epub ahead of print].

Enzymatic sialylation of IgA1 o-glycans: implications for studies of IgA nephropathy.
Takahashi K et al. PLoS One. 2014 Jun 11;9(2):e99026. doi: 10.1371/journal.pone.0099026. eCollection 2014.

Small Molecule Enhancers of Rapamycin induce apoptosis in Myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
Nekova TS et al. Br J Haematol. 2014 Jun 11. doi: 10.1111/bjh.12967. [Epub ahead of print].

Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1.
Soriani A et al. J Immunol. 2014 Jun 9. pii: 1400271. [Epub ahead of print].

Neoplastic Plasma Cell Aberrant Antigen Expression Patterns and Their Association with Genetic Abnormalities.
Salama ME et al. Leuk Lymphoma. 2014 Jun 10:1-21. [Epub ahead of print].

shRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Wu SQ et al. Int J Mol Med. 2014 Aug;34(2):616-23. doi: 10.3892/ijmm.2014.1798. Epub 2014 Jun 6.

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Liu N et al. Sci Rep. 2014 Jun 10;4:5240. doi: 10.1038/srep05240.

Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment.
Abdi J et al. Biomark Res. 2014 May 30;2:10. eCollection 2014.

Aberrant promoter methylation of p15 INK4b and p16 INK4a genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis.
Wang X et al. Tumour Biol. 2014 Jun 8. [Epub ahead of print].

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.
Koldehoff M et al. Cancer Gene Ther. 2014 Jun 6. doi: 10.1038/cgt.2014.27. [Epub ahead of print].

Efficient transient transfection of human multiple myeloma cells by electroporation – an appraisal.
Steinbrunn T et al. PLoS One. 2014 Jun 5;9(6):e97443. doi: 10.1371/journal.pone.0097443. eCollection 2014.

Liposomal Bortezomib Nanoparticles via Boronic Ester Prodrug Formulation for Improved Therapeutic Efficacy in Vivo.
Ashley JD et al. J Med Chem. 2014 Jun 13. [Epub ahead of print].

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.
Manni S et al. Leukemia. 2014 Jun 4. doi: 10.1038/leu.2014.178. [Epub ahead of print].

AKT as a therapeutic target in multiple myeloma.
Keane NA et al. Expert Opin Ther Targets. 2014 Jun 6:1-19. [Epub ahead of print].

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.
Wen J et al. Br J Haematol. 2014 May 29. doi: 10.1111/bjh.12951. [Epub ahead of print].

Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma.
Li Z et al. Mol Med Rep. 2014 Aug;10(2):832-8. doi: 10.3892/mmr.2014.2285. Epub 2014 May 29.